Introduction

The prevalence of age-dependent neurodegenerative diseases (NDs), such as Alzheimer’s disease (AD), Parkinson’s diseases (PD), Amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD), has increased worldwide in parallel with the rise in life expectancy. The common features of these diseases include selective neurodegeneration of specific populations of neurons that occurs in an age-dependent manner in the human brain (Wyss-Coray, 2016). The selective neurodegeneration in NDs is closely associated with the accumulation of misfolded proteins in the affected brain regions, which is largely due to the impairment of cellular machinery to clear unwanted and toxic proteins or peptides in aged neurons (Rubinsztein, 2006). Thus, identification of a treatment of any of these NDs would have broad implications for developing therapeutics for a large number of patients with NDs.

So far, there has been no effective treatment of NDs despite great efforts and progress being made over the course of several decades. The failure to find effective cues for NDs is largely owing to our incomplete understanding of the pathological mechanism underlying selective neurodegeneration. Most of NDs cases are sporadic with unknown causes, making it difficult to investigate the pathogenesis of these diseases. However, some NDs are caused by genetic mutations, which have facilitated research on investigation of how the mutations cause the disease proteins to become misfolded and toxic to initiate selective neurodegeneration. AD, which is characterized by dementia resulting from extensive yet selective neuron death in the neocortex and hippocampus, is the most common NDs with more than 90% of patients being sporadic and less than 10% of AD cases caused by a single genetic mutation in the APP genes (Presenilin 1, Presenilin 2, and Amyloid precursor protein APP) (Lanoiselée et al., 2017). PD is the second most common NDs that affects more than 1% people over age 60. The pathologic hallmarks of PD are the preferential loss of dopamine (DA) neurons and formation of Lewy body inclusions in the substantia nigra pars compacta (Damier et al., 1999). Although the majority of PD cases are sporadic, approximate 10% PD patients are caused by mutations in the genes for alpha-synuclein, PINK1, Parkin, LRRK2 and other proteins (Deng et al., 2018). ALS is also a progressive neurodegenerative disease that particularly affects motor neurons in the brain and the spinal cord, resulting in the loss of muscle movement (Grad et al., 2017). About 5%–10% of ALS patients are the familial form of ALS that could be caused by various mutations of genetic loci, including TAR DNA-binding protein 43 (TDP-43), superoxide dismutase 1 (SOD1), fused in sarcoma (FUS), and C9ORF72 (Neumann et al., 2006; Turner et al., 2013). Of many important NDs, HD is a mono-genetic disorder and represents a family of NDs that are caused by a CAG repeat expansion, which is translated to an expanded polyglutamine (polyQ) repeat in the disease proteins (Orr and Zoghbi, 2007; Tabrizi et al., 2020). In HD, the polyQ expansion encoded by an expanded CAG repeat (>36 CAGs) in exon 1 of the HD gene causes huntingtin (HTT) to misfold and aggregate in the patient brain, resulting in the preferential loss of the medium spiny neurons in the striatum and extended neurodegeneration in various brain regions as HD progresses (Bates et al., 2015). The genetic mutations identified in NDs have enabled the generation of various animal models harboring the disease mutations, which have greatly advanced our understanding of the pathogenesis of NDs.

Animal models that can recapitulate key pathological changes in the patient brains would be important for developing effective therapeutic strategies. Various species of animal models for NDs have been investigated, including fruit flies, rodents, dogs, sheep, pigs and non-human primates (Dawson et al., 2018). Among those species, rodents are the most widely used animal model for generating disease models due to their relatively short life span, easier and rapid breeding, lower costs, and available genetic editing techniques. Particularly, there are versatile genetic tools to establish loss- or gain-of-function mouse models, and genetically modified rodent models have provided important insights into the pathogenesis and therapeutics for neurodegenerative diseases. However, most of these rodent models fail to recapitulate the overt and typic neurodegeneration seen in the patients (Deng and Siddique, 2000; Crook and Housman, 2011; Dawson et al., 2018). This drawback apparently prevents the rigorous evaluation of the therapeutic effects on neurodegeneration. Recently, several large animal models carrying human genetic mutations are found to more faithfully mimic the important nature of selective neurodegeneration (Yang et al., 2021a). Because large animal models of HD, PD, and ALS have been successfully established and published, we will focus on the animal models of these diseases and discuss the important pathogenic insights from the large animal models.

Lack of overt neuronal loss in rodent models of neurodegenerative diseases

It would be worth discussing some important rodent models of NDs prior to describing large animal models, as these rodent models have been widely studied in the field and shed light on the pathogenesis of NDs. Various genetically modified mouse models of HD have been established and revealed that N-terminal fragments of mutant Htt with expanded polyQ repeats can accumulate in the brain to affect movement and neuronal function (Crook and Housman, 2011; Farshim and Bates, 2018). This idea is supported by the more severe phenotypes of transgenic mice expressing truncated N-terminal Htt fragments than those caused by full-length mutant Htt (Farshim and Bates, 2018). Because overexpressing N-terminal mutant Htt could cause phenotypes that may not occur in humans when full-length mutant Htt is expressed at the endogenous level, several HD knock-in mouse models were generated to express an expanded CAG/glutamine repeat in the endogenous mouse HD gene. However, there is no overt and selective medium spiny neuronal loss in HD knock in mouse models (Levine et al., 2004; Crook and Housman, 2011).

Mutations in the human PINK1 and PRKN gene were found to result in autosomal recessive Parkinson’s disease (PD) that is featured by neurodegeneration in association with mitochondria dysfunction (Valente et al., 2004; McInerney-Leo et al., 2005; Corti et al., 2011; Pickrell and Youle, 2015). However, the Pink1 or Prkn KO mouse models are unable to recapitulate selective and overt neurodegeneration seen in PD (Kitada et al., 2007; Xiong et al., 2009; Gispert et al., 2009; Akundi et al., 2011) or validate the important in vitro findings for the function of PINK1/Parkin in mitophagy (Whitworth and Pallanck, 2017; Cummins and Gotz, 2018). Moreover, triple knockout of three PD related genes of Prkn/Pink1/DJ-1 at the same time in mouse models have not shown any obvious neuronal degeneration even in very old age (Kitada et al., 2009).

Since mutations in the nuclear TDP-43 gene cause ALS, rodent models carrying TDP-43 mutations were widely used to investigate ALS pathogenesis. TDP-43 is a nuclear protein that is involved in a variety of cellular functions including gene transcription, RNA processing, and protein homeostasis (Lagier-Tourenne and Cleveland, 2009; Polymenidou et al., 2011; Weishaupt et al., 2016). In patients with TDP-43 mutations or some pathological conditions such as fronto-temporal lobar degeneration (FTLD), however, the nuclear TDP-43 is redistributed in the cytoplasm and forms cytoplasmic inclusions (Neumann et al., 2006; Arai et al., 2006; Chen-Plotkin et al., 2010). This cytoplasmic redistribution of TDP-43 protein in human brains can lead to a loss of function in the nucleus and a gain of toxicity in the cytoplasm (Huang et al., 2012; Philips and Rothstein, 2015). Although some mouse models can have the minimal level of cytoplasmic TDP-43 (Wegorzewska et al., 2009; Wils et al., 2010; Mitchell et al., 2015), most of TDP-43 mutant mice show the predominantly nuclear localization of TDP-43 and do not reproduce the key pathological hallmark of cytoplasmic mislocalization of TDP-43 (Wegorzewska et al., 2009; Shan et al., 2010; Huang et al., 2012; Yan et al., 2014; Philips and Rothstein, 2015).

Thus, although the mouse models can remarkably recapitulate protein misfolding and aggregation seen in the patient brains (Zoghbi and Botas, 2002; Dugger et al., 2017; Soto and Pritzkow, 2018), most of the mouse models cannot fully mimic the symptoms and pathologies of these neurodegenerative diseases. This phenomenon could be due to species differences determined by genomic, molecular, and anatomic differences between rodents and humans.

Pronounced differences in the brains of different species

There are considerable differences in brain development, anatomical structure, cognitive and behavioral complexity between small and large animals, which explain why many human neurological and neuropsychiatric diseases are inadequately modeled in rodents (Izpisua Belmonte et al., 2015). For example, a larger cortical progenitor pool in the outer subventricular zone (SVZ), which is not present in rodents (Smart et al., 2002), is required for cortical gyrification (Rash et al., 2019). Otani et al. described that cortical progenitor cells expand their population for an extended period during the neurogenesis in primates (Otani et al., 2016), but such expansion is not prominent in rodents (Gao et al., 2014). Consequently, the cerebral cortex differs 1000-fold in size between mouse and large animals (Defelipe, 2011; Herculano-Houzel, 2012). As a result, rodent brains are much smaller and lack the folding of the cortical surface whereas pig, monkey, and human share this important feature in their brains (Fig. 1). The increased neuronal number and cerebral cortex size lead to more complex neural architectures that determine cognitive abilities (Herculano-Houzel, 2012; Geschwind and Rakic, 2013) and can also impact pathological and behavioral phenotypes of animal models of NDs.

Figure 1
figure 1

Major differences in brain size and structures between rodents and large animals

Full size image

Aging processes also differ significantly among different types of animals. Rodents normally live for less than 3 years, a short life span that may not be sufficient for the occurrence of neurodegeneration that usually takes decades to happen in humans. The rapid development and accelerated aging in small animals could render their brains or neuronal cells less vulnerable to insults or toxic proteins such that they lack robust neurodegeneration despite the presence of impaired brain function.

At the molecular level, the brains of large animals and humans share more similar patterns of gene expression than does the mouse brain (Bernard et al., 2012; Zeng et al., 2012; Hawrylycz et al., 2015; Bakken et al., 2016; Sousa et al., 2017; Zhu et al., 2018). Especially, transcriptional profiling in adult mice and humans demonstrated robust differences between neuronal and non-neuronal cell types and large-scale changes over the course of development (Darmanis et al., 2015; Molyneaux et al., 2015; Zeisel et al., 2015). In rat and human, there are 22% of genes showing different developmental trajectories, whereas only 9% of genes have different trajectories between rhesus monkey and human (Bakken et al., 2016). Thus, the brains of large animals may express the same molecules that are important for neuronal survival or death in humans but may not be essential in rodents or small animals.

Although pig is less similar to human than monkey, especially in cognition and emotion, the global structure of the pig brain is approximately equal to that of humans. In addition, the body size and physiology of pigs resemble those of humans, allowing for safe dosage ranges to be defined in drug development studies and toxicological testing. Pigs have an early sexual maturity (5–8 months) as well as a relatively short gestation period (about 114 days) and are able to produce multiple offspring (about 10–12 piglets per liter). In addition, the pig endogenous genes can be edited via somatic cell nuclear transfer (SCNT) to produce knock-in or knockout models. All these advantages make pigs a promising and alternative large animal model for investigating human diseases (Lunney et al., 2021).

Strategies for generating large animal models of neurodegenerative diseases

Identification of genetic mutations responsible for NDs opened up an avenue to genetically express the same mutant genes in animals to model NDs. Unlike mouse models that can be generated using their embryonic stem cells after in vitro genome editing, large animal models were often generated by transgenic approach that introduces exogenous mutant genes in the fertilized eggs. However, the phenotypes of transgenic animals are influenced by the copy numbers of the transgene and its location in the host genome. The recently developed new genome-editing technologies, such as the CRISPR/Cas9 system, makes revolutionary changes in modifying endogenous genomes in large animals. For example, germline genome editing in non-human primates can be achieved by injection of the CRISPR/Cas9 system into the fertilized eggs (Zhao et al., 2017; Zhang et al., 2018; Yang et al., 2019b; Zhou et al., 2019). Since most genetic diseases result from point mutations, the development of base editor system is particularly useful to introduce or correct a point mutation in the endogenous genes (Xie et al., 2019; Chen et al., 2020; Wang et al., 2020).

However, the long-life cycle and high costs of non-human primates prevent the widespread use of genetically modified monkey models. Since CRISPR/Cas9 can also target genes in adult neuronal cells (Incontro et al., 2014; Swiech et al., 2015; Yang et al., 2021b), it can be directly applied to the brains of adult monkeys via stereotaxic injection of viral expression vectors. Such studies would allow one to explore the function of mutant genes in adult monkey and also to more rapidly generate monkey models that can mimic brain region-specific or age-dependent neurodegeneration. For example, because of the gain of toxicity of α-synuclein, stereotaxic injection of lentiviral vectors expressing mutant α-synuclein (A53T) into the substantia nigra of monkeys at different ages was performed (Yang et al., 2015). Li et al. also used AAV9-delivered CRISPR/Cas9 system to directly co-edit PINK1 and DJ-1 genes in the substantia nigras (SNs) of monkeys at different ages (Li et al., 2021). Our group recently depleted the monkey brain PINK1 gene via AAV-mediated CRISPR/Cas9 in adult monkey brain (Yang et al., 2021b). Furthermore, genome editing could be used to modify genes in different cell types (such as neurons or glia) with specific promoters for investigating gene functions in different brain cell types.

Pig models of NDs can be established using SCNT to introduce genetic mutations in the endogenous pig genes to generate knock-in and knockout models (Hauschild et al., 2011; Zhou et al., 2015; Ryu et al., 2018; Yan et al., 2018). Wang et al. established a pROSA26-Cas9 pig line with Cre-inducible Cas9 expression to facilitate genome editing in pigs (Wang et al., 2017). Expression of the mutant genes at the endogenous level would avoid artificial effects of overexpressed transgene. Furthermore, SCNT in combination with CRISPR/Cas9 allowed for selecting embryos expressing a single mutation, leading to the expression of the same mutant gene ubiquitously in each cell and eliminating the concern of mosaicism of gene targeting caused by CRIPSR/Cas9. The development of genome editing technology has accelerated the use of pigs, non-human primates, and other large animals to model human diseases (Fig. 2).

Figure 2
figure 2

Common strategies to generate animal models of neurodegenerative diseases

Full size image

Genetically modified large animal models of neurodegenerative diseases

Huntington’s disease (HD)

Genetically modified large animal models are summarized in Table 1. Of these animal models, HD transgenic monkeys were the first transgenic monkey model of human diseases, which was established by injecting lentiviruses into fertilized rhesus monkey oocytes to express exon 1 (1–67) mutant HTT containing 84Q (Yang et al., 2008). The HD monkeys showed abundant HTT aggregates in the neuronal nuclei and processes as seen in the brains of HD mouse models and patients, but died postnatally with severe neurodegeneration (Yang et al., 2008), in contrast to the transgenic HD mice that expressed the same transgenic HTT but could survive after birth without overt neurodegeneration (Davies et al., 1997).

Table 1 Large animal models of neurodegenerative diseases.
Full size table

Different transgenic pigs were also generated to model HD. Transgenic pigs expressing N-terminal mutant HTT 105Q (N208-105Q) were generated via SCNT, but most of the transgenic HD piglets died postnatally (Yang et al., 2010). Another group generated transgenic HD pigs via lentiviral infection of porcine embryos that expressed a large fragment of mutant HTT (1–548) containing 124Q. However, these transgenic HD pigs showed much milder phenotypes and did not die after birth (Baxa et al. 2013; Schuldenzucker et al., 2017). Transgenic sheep that expressed full-length mutant HTT with 73Q and were also generated via microinjection into pronuclei of single-celled zygotes show very mild phenotypes (Jacobsen et al., 2010). Because viral infection or microinjection of fertilized oocytes can lead to various degrees of transgene expression in different types of cells, the distinct phenotypes in transgenic HD animals are clearly dependent on the transgene expression.

To express the mutant HTT gene in the endogenous genome of pigs, a HD knock-in pig model was generated via CRISPR/Cas9 and SCNT. This HD KI pig model expressed an expanded polyCAG (150 CAG) in the endogenous HTT gene (Yan et al., 2018). Importantly, when full-length mutant HTT with 150Q was endogenously expressed in this HD pig model, it caused striking and selective neurodegeneration as well as movement disorders, effectively recapitulating the typical pathological and clinic features in HD patients. Furthermore, the expanded CAG repeats and neurological phenotypes of these HD KI pigs can be transmitted to next generations by germline (Yan et al., 2018), providing a valuable model for investigating the pathogenesis and therapeutics of HD.

Parkinson’s disease (PD)

Transgenic monkey models that overexpress mutant α-synuclein have been generated for investigating PD pathology and validated the neurotoxicity of mutant proteins (Giasson et al., 2002; Lee et al., 2002; Yang et al., 2015; Ip et al., 2017). However, the various expression levels of exogenous mutant proteins could compromise the phenotype outcomes such that it is difficult to compare the merits of each transgenic PD animal model. Based on the fact that genetic mutations in the PINK1, PRKN and DJ-1 genes caused PD via a loss-of-function mechanism, CRISPR/Cas9-targeting of these genes in the pigs and monkeys was performed. Interestingly, disrupting the PINK1 and PRKN genes in pigs via CRISPR/Cas9 did not produce any neurodegeneration and severe phenotypes (Zhou et al., 2015; Wang et al., 2016), like Pink1 KO mouse models that show no neurodegeneration or severe phenotypes (Zhou et al., 2007; Gautier et al., 2008; Kitada et al., 2009). Chen et. al utilized the paired gRNA/Cas9-D10A nickases to disrupt the monkey PINK1 in the fertilized monkey oocytes but did not observe PD phenotypes in the live mutant monkeys (Chen et al., 2021). It remains unknown whether the PINK1 protein is reduced in the brain of their monkey model, as only PINK1 mRNA from the targeted fibroblasts was reported to be decreased. Because the mosaicism of CRISPR/Cas9-mediated mutations can induce different extents of PINK1 loss and varying degrees of phenotypes and because the deficiency of PINK1 protein is correlated with the loss of neuronal cells in different tissues in the same monkey (Yang et. al., 2019b), it is important to examine the protein level of the targeted gene in different brain regions. On the other hand, injection of AAV into the monkey substantia nigra to co-edit the PINK1 and DJ-1 genes could mediate severe nigra dopaminergic cell loss and motor function deficits (Li et al., 2021).

It seems likely that the phenotypes of PINK1 targeted monkeys rely on the extent to which PINK1 is depleted. To ensure that PINK1 expression and function are completely lost, we used two gRNAs to disrupt the monkey PINK1 exon 2 and exon 4, resulting in a large PINK1 DNA fragment deletion in the monkey embryos. The newborn monkeys showed severe neurodegeneration or died postnatally (Yang et al., 2019b), demonstrating for the first time that PINK1 is essential for neuronal survive in the primate brain.

The phenotypes of PINK1 targeted monkeys are clearly different from the rodent models with deletion of the mouse Pink1 gene. None of Pink1 knockout mouse models showed the typical degeneration of dopaminergic neurons seen in the brains of PD patients (Perez and Palmiter, 2005; Zhou et al., 2007; Kitada et al., 2007, 2009). Similarly, deletion of the gene for Parkin, which works together with Pink1 in protecting against mitochondrial damage, did not produce any obvious degeneration either in the mouse brain (Goldberg et al., 2003; Perez and Palmiter, 2005; Kitada et al., 2009). The remarkable differences between rodents and monkeys in PINK1 deletion-mediated phenotypes underscore the value of using the non-human models to investigate the function of PINK1.

Amyotrophic lateral sclerosis (ALS)

The absence of predominant distribution of mutant TDP-43 in the cytoplasm, a pathological hallmark of ALS, in the rodent models motivated us to use non-human primates for investigation. We previously created the TDP-43 transgenic pig model that exhibited the cytoplasmic distribution of TDP-43 as seen in patient brains (Wang et al., 2015). To investigate the subcellular distribution of mutant TDP-43 in the monkey brain, we directly injected viral vector expressing mutant TDP-43 into the rhesus monkey brain cortex and substantia nigra (Yin et al., 2019). The majority of mutant TDP-43 was distributed in the cytoplasm of the monkey brain, contrary to the nuclear accumulation of TDP-43 in the mouse brain (Yin et al., 2019) but consistent with the cytoplasmic distribution of mutant TDP-43 in the monkey spinal cord (Uchida et al., 2012).

The human SOD1 mutations could cause familial ALS. Although SOD aggregates are mainly found in the cytoplasm, intranuclear SOD1 aggregates were also seen in some postmortem brains of ALS patients with SOD1 mutations (Kakita et al., 1997; Seilhean et al., 2004; Forsberg et al., 2011). Mutant SOD1 transgenic mice are most widely used animal models of ALS and have given us important insights into the pathogenesis of ALS (Ferraiuolo et al., 2011; Philips and Rothstein, 2015). However, most of the transgenic SOD1 mouse models did not show intranuclear aggregates and lack substantial cortical motor neuronal degeneration, which is a fundamental feature of ALS patients (Philips and Rothstein, 2015). Yang et al. generated the SOD1 (G93A) transgenic pigs via the SCNT method (Yang et al., 2014). The transgenic SOD1 pigs showed hind limb motor defects and neuronal degeneration in dose- and age-dependent manners. Also, in the early disease stage, mutant hSOD1 did not form cytoplasmic inclusions, but showed nuclear accumulation and ubiquitinated nuclear aggregates, as seen in some ALS patient brains (Yang et al., 2014). The differences between transgenic SOD1 mice and pigs further support the idea that large animal models can more faithfully mimic the age-dependent and progressive pathological changes seen in the patient brains.

New insights from large animal models into disease mechanisms

A successfully established animal model of neurodegenerative disease should adequately recapitulate the important pathological features and important clinical phenotypes of patients. The current large animal models reviewed above have demonstrated important species-dependent differences in neuropathology. They would serve as important tools to investigate the pathogenesis and pathological events that may uniquely occur in humans and can therefore be new therapeutic targets.

HD KI pigs can be used to rigorously evaluate the involvement of mutant HTT in a number of important pathological events found in small animal models. One of the well-documented events in HD mice is the somatic CAG repeat instability in the striatum, a brain region that is preferentially affected in HD (Swami et al., 2009). Further investigation of CAG repeat lengths in various brain regions of HD KI pigs showed that the CAG repeats are fairly stable in the striatum (Bai et al., 2021). These findings point to the potential regulation of the somatic instability of CAG repeats by species-dependent factors and stress the role of polyglutamine toxicity rather than CAG instability in large animals. The therapeutic implication of these findings is that removing mutant HTT protein would be more important than correcting CAG instability at the DNA level.

Comparison of PINK1 KO models of mouse and monkey uncovered the unique expression and function of PINK1 in the primate brains, because PINK1 is undetectable in the mouse brain but abundantly expressed in the primate brain at the protein level (Yang et al., 2021b). This striking difference may explain why Pink1 knock out mouse models do not have overt neurodegeneration because Pink1 is not essential in rodents. PINK1 seems to have mitochondria-independent function and can phosphorylate a series of neuronal function-related proteins that are vital to neuronal survival in the primate brains (Yang et al., 2019a; Sun et al., 2021). Thus, genetic mutations such as a point mutation or a mutation in the non-kinase domain of PINK1 created in other monkey models may not be able to significantly affect PINK1 kinase function to elicit obvious neurodegeneration (Chen et al., 2021). Characterization of PINK1 targeted monkeys leads to a new theory that the primate PINK1 mainly functions as a kinase to maintain neuronal survival, which is different from the prevailing theory of mitophagy that is largely based on in vitro studies of stressed or damaged mitochondria (Fig. 3). The findings also implicate that improvement of dysfunction of PINK1 kinase, which is a druggable target, may be more effective than repair of damaged mitochondria in treating PINK1 mutation-mediated pathology in PD.

Figure 3
figure 3

New pathogenic insight of monkey models with PINK1 mutation. The prevalent theory for the function of PINK1 in mitophagy is largely based on in vitro studies (left). The in vivo studies of the primate brains suggest that PINK1 is a kinase to phosphorylate many neuronal proteins to maintain neuronal survival (right)

Full size image

The distribution of mutant TDP-43 (M337V) in the cytoplasm in the brains of rhesus monkeys and pigs (Uchida et al., 2012; Wang et al., 2015; Yin et al., 2019) highlights the values of large animal models for investigating the cytoplasmic toxicity of TDP-43. Subsequent investigation identified that the primate-specific caspase-4, which is not expressed in the mouse brain, was able to cleave TDP-43 and remove its NLS-containing N-terminal domain, resulting in the cytoplasmic accumulation of TDP-43 (Yin et al., 2019). The cytoplasmic mutant TDP43 could selectively reduce SQSTM1 expression in the monkey brain by reducing SQSTM1 mRNA stability via its binding to the unique 3’UTR sequence (GU/UG) of the primate SQSTM1 transcript (Fig. 4) (Yin et al., 2021). Thus, selective expression of modifiers or targets of the disease proteins in large animal models apparently contributes to the specific neuropathological events that may not occur in small animal models.

Figure 4
figure 4

New pathogenic insight of monkey models expressing mutant TDP-43. TDP-43 remains in the nucleus of rodent neurons to elicit nuclear toxicity. In the primate neurons, however, the primate-specific caspase-4 cleaves TDP-43 to cause truncated TDP-43 to redistribute in the cytoplasm, resulting in the cytoplasmic toxicity

Full size image

Challenges of using large animal models and resolutions

Although recently established large animal models of NDs offer fresh and important insights into the pathogenesis of NDs, there are notable limitations for generating large animal models. The high animal cost, the current low efficiency in gene targeting, especially for knock-in and conditional knockout or gene expression, in large animals and extensive time required for studies of large animals are obvious concerns for widely using such animal models for research. For example, pigs have a sexual maturity of 5–8 months and the gestation period of about 114 days. For monkeys, the sexual maturity takes much longer time (4–5 years), the gestation period lasts for about 165 days, and each female animal often produces a single offspring each year. In addition, generation of embryonic genome edited non-human primate models is technically challenging and labor intensive, as multiple processes including hormonal superovulation, embryo transfer with surgical implantation, and experienced animal care, would require the well-equipped animal facility, enough animal resources, and a highly trained team.

Additionally, CRISPR/Cas9 system creates the mosaic mutations that may result in various types of mutations and different cellular phenotypes. The mosaicism in offspring can be reduced by outcrossing the mosaic founders with wild type animals. However, it will take years to eliminate mosaicism in large animal models, especially for the non-human primates that require 4–5 years of sexual maturity to produce next generation. In pig models, however, the gene editing tools combined with SCNT have been successfully to establish the pig models that carry the same single genetic mutation as in human patients. SCNT was also applied to the non-human primate, and the results demonstrate the feasibility to generate knock-in non-human primate models (Liu et al., 2018), but the efficiency is much lower.

Several other technical hurdles also need to be resolved. Although the mosaic mutations in different animals may not yield the same phenotypes, one can analyze the correlation of genetic mutations and phenotypes at the cellular level, which can be achieved by imaging and RNAseq analysis at single cell resolution (Zhang et al., 2021). Designing specific gRNAs and controlling Cas9 expression should minimize the off-targets and increase the specificity of CRSIPR/Cas9-mediated gene targeting. The heterogeneity in genetic backgrounds of large animals may lead to more variability in behaviors such that sufficient numbers of large animals are required to make a sound conclusion. For example, cognitive impairment is a common non-motor symptom in patients of NDs. Most of the NDs exhibit different extents of impaired cognitive functions that can be measured using Wisconsin general test apparatus (WGTA) (Zhou et al., 2019). Anxiety-associated behaviors or motor deficits can be examined and monitored by the locomotion activity assay (Liu et al., 2016). To assess sleep disturbance in large animal models, daily home-cage videos should be recorded at specific time points. Thus, the robust and automated systems for tracking and analyzing behavior will be important for accurately assessing species-specific normal behavior, disease phenotypes, and data reproducibility.

Alternatively, genetic modification can be performed in somatic cells to mirror neuropathology in the specific brain regions in large animals. The direct administration of AAV expressing gRNA/Cas9 or transgenes into specific brain regions of large animals at multiple developmental stages or different ages could more rapidly recapitulate brain region-dependent or age-related neuropathology. Treatment of gene-targeted animals with environmental stress or chemicals that induce oxidative stress could also facilitate disease progression, as oxidative stress has been implicated in the progression of a number of NDs. Moreover, the continued improvement of viral vectors that can readily penetrate the blood–brain barrier may greatly facilitate the delivery of the gRNA/Cas9 system or transgenes in the brains of large animals (Chan et al., 2017; Goertsen et al., 2021).

Conclusions and perspectives

This review updates the large animal models of neurodegenerative diseases, including HD, PD and ALS. Although investigation of large animal models led to new discoveries of important pathological events or mechanism that have not been found in small animals, there are challenges and limitations that are largely stemmed from the costly and time-consuming investigation. However, the important information gained from the large animal models would be highly valuable for understanding the pathogenic mechanisms and identifying new therapeutic targets. Given the lack of obvious neurodegeneration phenotypes in most of genetically modified rodent models, the demand for establishing large animal models to study neurodegenerative diseases is well-appreciated, and the publications of large animal models with gene editing are steadily increased recently. It is expected that more of large animal models would be embraced as the preferred model for human diseases and translational medicine research. Moreover, the important information gained from large animal models would be highly valuable for generating more humanized mouse models. Specifically, important differences in pathological phenotypes between small and large animals would guide us to create humanized mouse models that can more closely emulate the important pathological features seen in large animal models and patients.